Portfolio of Immune Checkpoint Inhibitor Stocks
Here are 4 companies that offer immune checkpoint inhibitor cancer treatments:
- AstraZeneca (AZN) - durvalumab Imfinzi
- Bristol-Myers Squibb (BMY) - nivolumab Opdivo and ipilimumab Yervoy
- Merck (MRK) - pembrolizumab Keytruda
- Roche Holding (RHHBY) - atezolizumab TECENTRIQ
|4 Checkpoint Inhibitor Stocks|
Stock Returns & Price Chart
|Roche Holding AG||RHHBY|
|Price data from Quandl as of most recent close.|
The 3 stocks included in the portfolio
computations are: AZN, BMY and MRK. The current value of the portfolio assumes that $3,333.33 was invested (total of $10,000) in each stock at its closing monthly price for the current date in 2009. All prices are adjusted for splits and dividends. RHHBY was excluded from the portfolio computations because of insufficient price data.
To inspect the performance of the Checkpoint Inhibitor Stocks portfolio, see the chart of portfolio below. Portfolio values are computed using monthly closes for stocks from Quandl.
The current value of a $10,000 investment is $39,027. The percent return is 290.27%. The annualized return is 14.59%.